ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management
Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year…
Scaling Smart: Strengthen Systems Before Expanding
ECCA and TTEC Release “Visionary Voices” Research on the Future of Contact Centre Sales in Europe